

**Name:** Woong-Yang Park, M.D., Ph.D.

**Work Address:** Samsung Genome Institute  
Samsung Medical Center  
81 Irwonro, Gangnamgu  
Seoul 06351, KOREA

**Education:**

1988 M.D. Seoul National University, Korea  
1995 Ph.D. (Biochemistry) Seoul National University, Korea  
1998 Postdoctoral Fellow (Neuro-Oncology), Rockefeller University, USA

**Board Certification and Licensure:**

1988 License of Medical Doctor, Korea

**Brief Chronology of Employment:**

1988-1996 Research Assistant/Lecturer, Dong-A University, Korea  
1998-2012 Professor, Seoul National University College of Medicine, Korea  
2004-2006 Visiting Professor, Rockefeller University, USA  
2008-2010 Associate Dean of Student Affairs, Seoul National University College of Medicine, Korea  
2010-2015 Guest Professor, Jilin University College of Medicine, China  
2010-2012 Chairman, Department of Biomedical Sciences, Seoul National University, Korea  
2012-2012 Chairman, Department of Biochemistry, Seoul National University, Korea  
2013- Director, Samsung Genome Institute, SMC, Korea  
2013- Professor, Sungkyunkwan University College of Medicine, Korea  
2018- Founder and CEO, GENINUS Inc., Korea

**Awards, Scholarships and Other Honors:**

2002 Young Scientist Award, Korea Society for Biochemistry and Molecular Biology  
2002 Young Medical Scientist Award, Seoul National University Hospital  
2004 Visiting Professor Fellowship, LG Foundation  
2011 Frontier Research Scientist, Korea National Academy of Science and Technology  
2014 EMM Award, Korea Society for Biochemistry and Molecular Biology  
2016 Prime Minister's Commendation

**Professional Activities:**

2012-2015 Member, Scientific Committee, International Rare Disease Research Consortium  
2014- Editorial Board, Genome Biology  
2017-2018 National Science & Technology Committee, MSIP, Korea  
2018-2018 Chairman, Healthcare Part, Presidential Committee on 4th Industrial Revolution, Korea  
2018- Member, National Bio R&D Committee, MSIP, Korea

**Bibliography (SCI paper only)**

1. Lee H, Joung JG, Shin HT, Kim DH, Kim Y, Kim H, Kwon OJ, Shim YM, Lee HY, Lee KS, Choi YL, **Park WY**, Hayes DN, Um SW. Genomic alterations of ground-glass nodular lung adenocarcinoma. *Sci Rep*. 2018 May 16;8(1):7691.
2. Kan Z, Ding Y, Kim J, Jung HH, Chung W, Lal S, Cho S, Fernandez-Banet J, Lee SK, Kim SW, Lee JE, Choi YL, Deng S, Kim JY, Ahn JS, Sha Y, Mu XJ, Nam JY, Im YH, Lee S, **Park WY**, Nam SJ, Park YH. Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures. *Nat Commun*. 2018 Apr 30;9(1):1725. doi: 10.1038/s41467-018-04129-4.
3. Jeong SH, Kim HB, Kim MC, Lee JM, Lee JH, Kim JH, Kim JW, **Park WY**, Kim SY, Kim JB, Kim H, Kim JM, Choi HS, Lim DS. Hippo-mediated suppression of IRS2/AKT signaling prevents hepatic steatosis and liver cancer. *J Clin Invest*. 2018 Mar 1;128(3):1010-1025.

4. Chang MY, Lee C, Han JH, Kim MY, Park HR, Kim N, **Park WY**, Oh DY, Choi BY. Expansion of phenotypic spectrum of MYO15A pathogenic variants to include postlingual onset of progressive partial deafness. *BMC Med Genet*. 2018 Feb 27;19(1):29.
5. Moon HS, Je K, Min JW, Park D, Han KY, Shin SH, **Park WY**, Yoo CE, Kim SH. Inertial-ordering-assisted droplet microfluidics for high-throughput single-cell RNA-sequencing. *Lab Chip*. 2018 Feb 27;18(5):775-784.
6. Cha S, Kang JH, Lee JH, Kim J, Kim H, Yang YJ, **Park WY**, Kim J. Impact of Genetic Variants on the Individual Potential for Body Fat Loss. *Nutrients*. 2018 Feb 26;10(3).
7. Kim JY, Yu JH, Nam SJ, Kim SW, Lee SK, **Park WY**, Noh DY, Nam DH, Park YH, Han W, Lee JE. Genetic and Clinical Characteristics of Phyllodes Tumors of the Breast. *Transl Oncol*. 2018 Feb;11(1):18-23.
8. Lee H, Lee KW, Lee T, Park D, Chung J, Lee C, **Park WY**, Son DS. Performance evaluation method for read mapping tool in clinical panel sequencing. *Genes Genomics*. 2018;40(2):189-197.
9. Han KY, Kim KT, Joung JG, Son DS, Kim YJ, Jo A, Jeon HJ, Moon HS, Yoo CE, Chung W, Eum HH, Kim S, Kim HK, Lee JE, Ahn MJ, Lee HO, Park D, **Park WY**. SIDR: simultaneous isolation and parallel sequencing of genomic DNA and total RNA from single cells. *Genome Res*. 2018 Jan;28(1):75-87.
10. Youn J, Lee C, Oh E, Park J, Kim JS, Kim HT, Cho JW, **Park WY**, Jang W, Ki CS. Genetic variants of PARK genes in Korean patients with early-onset Parkinson's disease. *Neurobiol Aging*. 2019 Mar;75:224.
11. Kim JY, Lee E, Park K, Jung HH, **Park WY**, Lee KH, Sohn J, Lee KS, Jung KH, Kim JH, Lee KH, Im SA, Park YH. Molecular Alterations and Poziotinib Efficacy, a pan-HER inhibitor, in Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancers: Combined Exploratory Biomarker Analysis from a Phase II Clinical Trial of Poziotinib for Refractory HER2-positive Breast Cancer Patients. *Int J Cancer*. 2019 Feb 5. doi: 10.1002/ijc.32188. [Epub ahead of print]
12. Moon SH, Kim J, Joung JG, Cha H, **Park WY**, Ahn JS, Ahn MJ, Park K, Choi JY, Lee KH, Kim BT, Lee SH. Correlations between metabolic texture features, genetic heterogeneity, and mutation burden in patients with lung cancer. *Eur J Nucl Med Mol Imaging*. 2019 Feb;46(2):446-454.
13. Kim Y, Lee B, Shim JH, Lee SH, **Park WY**, Choi YL, Sun JM, Ahn JS, Ahn MJ, Park K. Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC. *J Thorac Oncol*. 2019 Feb;14(2):193-202.
14. Ahn JH, Kim AR, Lee C, Kim NKD, Kim NS, **Park WY**, Kim M, Youn J, Cho JW, Kim JS. Type 1 Sialidosis Patient With a Novel Deletion Mutation in the NEU1 Gene: Case Report and Literature Review. *Cerebellum*. 2019 Jan 11. doi: 10.1007/s12311-019-1005-2. [Epub ahead of print]
15. Lee J, Shim JH, **Park WY**, Kim HK, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ. Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer. *Cancer Res Treat*. 2019 Jan;51(1):408-412.
16. Lee SH, Lee B, Shim JH, Lee KW, Yun JW, Kim SY, Kim TY, Kim YH, Ko YH, Chung HC, Yu CS, Lee J, Rha SY, Kim TW, Jung KH, Im SA, Moon HG, Cho S, Kang JH, Kim J, Kim SK, Ryu HS, Ha SY, Kim JI, Chung YJ, Kim C, Kim HL, **Park WY**, Noh DY, Park K. Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients. *Cancer Res Treat*. 2019 Jan;51(1):211-222.
17. Cho HJ, Zhao J, Jung SW, Ladewig E, Kong DS, Suh YL, Lee Y, Kim D, Ahn SH, Bordyuh M, Kang HJ, Sa JK, Seo YJ, Kim ST, Lim DH, Dho YS, Lee JI, Seol HJ, Choi JW, **Park WY**, Park CK, Rabadan R, Nam DH. Distinct genomic profile and specific targeted drug responses in adult cerebellar glioblastoma. *Neuro Oncol*. 2019 Jan 1;21(1):47-58. doi: 10.1093/neuonc/noy123.
18. Yun JW, Lee S, Ryu D, Park S, **Park WY**, Joung JG, Jeong J. Biomarkers Associated with Tumor Heterogeneity in Prostate Cancer. *Transl Oncol*. 2019 Jan;12(1):43-48.
19. Chung J, Lee KW, Lee C, Shin SH, Kyung S, Jeon HJ, Kim SY, Cho E, Yoo CE, Son DS, **Park WY**, Park D. Performance evaluation of commercial library construction kits for PCR-based targeted sequencing using a unique molecular identifier. *BMC Genomics*. 2019 Mar 14;20(1):216.
20. Oh BY, Shin HT, Yun JW, Kim KT, Kim J, Bae JS, Cho YB, Lee WY, Yun SH, Park YA, Park YH, Im YH, Lee J, Joung JG, Kim HC, **Park WY**. Intratumor heterogeneity inferred from targeted deep sequencing as a prognostic indicator. *Sci Rep*. 2019 Mar 14;9(1):4542.
21. Shin SH, Kim YJ, Lee D, Cho D, Ko YH, Cho J, **Park WY**, Park D, Kim SJ, Kim WS. Analysis of circulating tumor DNA by targeted ultra-deep sequencing across various non-Hodgkin lymphoma subtypes. *Leuk Lymphoma*. 2019 Feb 18:1-10
22. Kim BJ, Kim DK, Han JH, Oh J, Kim AR, Lee C, Kim NK, Park HR, Kim MY, Lee S, Lee S, Oh DY, **Park WY**, Park S, Choi BY. Clarification of glycosylphosphatidylinositol anchorage of OTOANCORIN and human OTOA variants associated with deafness. *Hum Mutat*. 2019 Feb 10. doi: 10.1002/humu.23719. [Epub ahead of print]